1Ripley DP, Brown JM, E,erett CC, et al. Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE - MARC 2): A prospective, multi- center, randomized trial of diagnostic strategies in suspected coro- nary heart disease[ J] Am Heart J, 2015, I69(1) : 17 -24.
2Sin NL, Yaffe K, Whooley MA. Depressive Symptoms, Cardiovas- cular Disease Severity, and Functional Status in Older Adults with Coronary Heart Disease: The Heart and Soul Study [ J]. J Am Geriatr Soc, 2015, 63(1) : 8 -15.
3Zhang XH, Lu ZL, Liu L. coronary heart disease in China[ J]. Heart, 2008, 94(9): 1126- 1131.
4U.S. Depa]ment of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for industry: patient - reported outcome measures: use in medical product development to support labeling claims: draft guidance[J]. Health Qua] Life Out- comes, 2006, 4 (6) : 1 - 20.
5Bruno P, Marie - Christine I, Stefan H, et al. Validation of the French version of the MacNew heart disease health - related quality of life questionnaire [ J ] Arch Cardiovasc Dis, 2015, 108 (2) : 107 - 117.
6Keller SD, Ware JE Jr, Bentler PM, et al. Use of Structural E- quation Modeling to Test the Construct Validity of the SF - 36 Health Survey in Ten Countries: Results from the IQOLA Project [J]. JClinEpidemiol, 1998, 51(11): 1179 -1188.
7Ware JE Jr, Kosinski M, Gandek B, et al. The factor structure of the SF - 36 Health Survey in 10 countries : resuhs from the IQOLA Project. International Quality of Life Assessment[ J]. J Clin Epi- demiol, 1998, 51(11): 1159-1165.
